Clinical Trials Logo

Clinical Trial Summary

While preliminary data show that oral nicotinamide riboside (NR) supplementation increases myocardial levels of oxidized nicotine-adenine dinucleotide (NAD+) levels in mice, there has been no direct evidence that suggests oral NR increases NAD+ levels or improves mitochondrial function in human hearts. This Pilot Study is designed to obtain feasibility data for a planned, larger study testing the hypothesis that oral NR supplementation will increase myocardial NAD+ levels and improve cardiomyocyte mitochondrial function in participants with advanced heart failure planned for elective left ventricular assist device (LVAD) implantation. To demonstrate safety and feasibility of NR in this patient population, the investigators propose to enroll 5 participants planned for LVAD implantation in a Pilot Study of NR in which participants will receive NR, up-titrated over 3 days to a final NR dose of 1000mg twice daily. Blood and myocardial tissue analyses collected previously from age- and gender-matched LVAD recipients will serve as controls.


Clinical Trial Description

This Pilot Study will examine the following Aims:

Aim 1: Enroll 5 participants scheduled for elective left ventricular assist device (LVAD) placement into an open-label study of nicotinamide riboside (NR).

a. Participants will have labs (including safety panels) drawn at baseline (Day 1), then receive escalating doses of NR to a maximum dose of 1000mg twice daily by Day 3. Participants will be continued on NR at 1000mg twice daily until LVAD implantation surgery.

On the morning of LVAD implantation Surgery (Day 5 or later), participants will have final labs drawn. Samples of fresh cardiac tissue removed from the left ventricular apex during LVAD implantation surgery will be collected in the operating room. The primary analyses will be performed on NR-treated participants who were on the maximum NR dose of 1000mg twice daily for at least 2 days prior to LVAD implantation surgery. The maximum duration of NR administration will be capped at 14 days. If the surgery doesn't happen by then, the participant will be withdrawn from the study.

Aim 2: Determine the effect of NR (as compared to historical controls) on levels of the oxidized and reduced forms of nicotine-adenine dinucleotide (NAD+ and NADH, respectively), mitochondrial function and its regulation through modifications of the epigenome in the failing myocardium.

1. Measure NAD+ and NADH levels in the blood and myocardium of the participants.

2. Assess mitochondrial morphology and function in cardiac tissue using, respectively, electron microscopy (EM) and isolated mitochondria.

3. Determine protein acetylation in the mitochondrial and non-mitochondrial compartments and changes in nuclear gene regulation.

Aim 3: Test the hypothesis that NR improves mitochondrial function and reduces inflammatory response in heart failure (HF) patients receiving NR (as compared to historical controls).

1. Measure mitochondrial function in peripheral blood mononucleated cells (PBMC).

2. Determine the inflammatory response in PBMC.

3. Compare effects on the circulating inflammasome vs. myocardial inflammation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03727646
Study type Interventional
Source University of Washington
Contact Laura McMartin
Phone 206-616-5910
Email mcmartin@uw.edu
Status Recruiting
Phase Early Phase 1
Start date September 26, 2018
Completion date July 26, 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03519477 - Comprehensive Medication Monitoring on Heart Failure Patient Outcomes N/A
Not yet recruiting NCT03202329 - Evaluation of Post-operative, Nurse-based Heart Failure Care in Non-cardiac Surgery N/A
Recruiting NCT02672618 - Clinical Research to Explore Manifestations of Heart Failure Using Infrared Thermal Imaging Technology N/A
Recruiting NCT03387813 - Hemodynamic-GUIDEd Management of Heart Failure N/A
Completed NCT03187470 - Left Ventricular Dyssynchrony in Multipole Pacing N/A
Recruiting NCT03385837 - Activity Level and Barriers to Participate of Cardiac Rehabilitation in Advanced Heart Failure Patients N/A
Completed NCT03722069 - Dietary Sodium Intake in Acute Heart Failure N/A
Recruiting NCT03341156 - Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation Phase 3
Not yet recruiting NCT03575910 - HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection
Recruiting NCT03389386 - Serum Catestatin Expression and Cardiometabolic Parameters in Patients With Congestive Heart Failure
Recruiting NCT03671122 - PREFERS (Preserved and Reduced Ejection Fraction Epidemiological Regional Study) Stockholm Heart Failure Study
Terminated NCT03102827 - High-Flow-Therapy for the Treatment of Cheyne-Stokes-Respiration in Chronic Heart Failure Phase 3
Recruiting NCT03200860 - Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure Phase 2
Recruiting NCT03720509 - A Study to Collect Information Related to the Cordio Medical System
Recruiting NCT03078972 - Effect of mechanIcal circulatoRy Support ON Exercise Capacity aMong pAtieNts With Heart Failure
Recruiting NCT03573427 - LV Endocardial CRT for Patients With Intermediate QRS Width